Your AI-Trained Oncology Knowledge Connection!

Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center : Episode 9

Strategies for AE Management with Tucatinib in Breast Cancer

February 23, 2024

By Carey K. Anders, MD
Heather Moore, CPP, PharmD

Opinion

Video

Heather Moore, CPP, PharmD, shares expert insights on the effective management of adverse effects related to tucatinib and other HER2 tyrosine kinase inhibitors (TKIs).

EP: 1.Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

EP: 2.Approaches for 1L Therapy and Restaging in Triple-Positive mBC

EP: 3.The Role of Radiotherapy in HER2+ mBC

EP: 4.Treatment Approaches for Triple-Positive mBC in the 2L Setting and Beyond

EP: 5.Treatment Considerations and AE Management Strategies with HER2-Directed Therapies

EP: 6.Patient Case Presentation: A 34-Year-Old Woman with HER2+ mBC and Brain Metastases

EP: 7.HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

EP: 8.BRIDGET: Preventing Secondary Brain Metastases in Advanced HER2+ Breast Cancer

Now Viewing

EP: 9.Strategies for AE Management with Tucatinib in Breast Cancer

EP: 10.D-TORCH: Topical Diclofenac for Reducing Hand Foot Syndrome with Capecitabine

EP: 11.Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases

EP: 12.Advancements in Treating Brain Metastases in HER2+ Breast Cancer

EP: 13.Radiation Necrosis with ADCs and Concurrent Radiotherapy for Brain Metastases

EP: 14.Strategies for AE Management with T-DXd in Breast Cancer

EP: 15.Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast Cancer

EP: 16.Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer

EP: 17.Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer

EP: 18.BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

EP: 19.Future Perspectives on HER2+ Breast Cancer Treatment

EP: 20.Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!